StopDown
Molbio Diagnostics logo
Stake sale · 1 October 2026Molbio DiagnosticsGoa-based diagnostics makermolbiodiagnostics.com ↗

Motilal Oswal fund sells 2% of Molbio

By · Editor ·

Stake saleGoaFounded 2000
  • Molbio Diagnostics is a Goa-based maker of molecular diagnostic tests and devices, now listed on the stock exchanges
  • A fund managed by Motilal Oswal Alternates sold about 2% of the company for ₹306 crore in open market trades on Wednesday
  • HDFC Mutual Fund bought roughly 2% at the same price, and the fund had sold a larger block worth ₹394 crore a week earlier

What happened

  • Business Excellence Trust III sold 23.28 lakh shares
  • Average price was about ₹1,315 a share
  • Sale value came to ₹306.26 crore
  • HDFC Mutual Fund picked up 23 lakh shares for ₹302.45 crore
  • The stock closed about 4% higher at ₹1,309.45

Why it matters

  • The fund held about 11.5% as of August, so it is trimming after listing
  • Large buyers stepping in shows institutional demand for the stock
  • A similar ₹394 crore sale last week points to a steady exit

The business

  • Molbio makes Truenat, a portable machine that runs lab-grade DNA tests (real-time PCR, a method that copies genetic material to detect germs) for infectious diseases such as TB.
  • It also sells a breast-screening device, a portable X-ray reading tool and digital pathology systems.
  • Buyers are government health programmes, aid agencies, hospitals and diagnostic labs, mostly in places with few central labs.
  • It earns by selling the machines and, more importantly, the test kits used with them; most revenue comes from TB kits sold to Indian and overseas public health programmes.
  • It is used in 90+ countries, with over 8,293 Truenat systems installed in India.
  • It is based in Verna, Goa, and does research through its subsidiary Bigtec Labs.

The founders

Sriram Natarajan

Co-founder, Executive Director and CEO
in
  • Leads commercial strategy, fundraising and government partnerships at Molbio.

Dr Chandrasekhar Bhaskaran Nair

Co-founder, Director and CTO
in
  • Directs the micro-PCR chip design and test development behind the Truenat platform.

Who put in money

In numbers

₹1,445.69 croreOperating revenue · FY2026
₹836.56 croreOperating revenue · FY2024
90+Countries served · 2026
8,293Truenat systems in India · 2026

Earlier rounds

  • 2021-05 · Series B · $19.2 million
  • 2022-09 · Growth round · $85 million
  • 2026-08-07 · Pre-IPO anchor round · Rs 281.5 crore
  • 2026-08 · IPO · Rs 939.7 crore

Up against

AbbottbioMérieuxQIAGENThermo Fisher ScientificMeril

The numbers around it

Molbio Diagnostics has 1 funding rounds in StopDown's archive.

#The numbers around it
WhenRoundAmountLed by
7 August 2026Pre-IPO anchor round₹281.5 CrUndefined

Healthcare & Life Sciences in October 2026: 20 rounds with a disclosed amount, $242 million in all; the biggest was Linux Laboratories ($70M). Every sector this year →

Read it as a card in the app

Everything on Molbio Diagnostics → · All startup news on 1 October 2026 →

Is this Molbio Diagnostics? Get your “Featured on StopDown” badge →